Compare CUBE & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CUBE | ARWR |
|---|---|---|
| Founded | 2004 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 10.2B |
| IPO Year | 2004 | 2009 |
| Metric | CUBE | ARWR |
|---|---|---|
| Price | $41.12 | $86.24 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 10 |
| Target Price | $44.00 | ★ $83.40 |
| AVG Volume (30 Days) | ★ 1.9M | 1.8M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 5.34% | N/A |
| EPS Growth | N/A | ★ 99.80 |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $1,123,110,000.00 | $16,142,321.00 |
| Revenue This Year | $0.66 | N/A |
| Revenue Next Year | $2.82 | N/A |
| P/E Ratio | $111.75 | ★ N/A |
| Revenue Growth | ★ 5.33 | N/A |
| 52 Week Low | $35.09 | $14.30 |
| 52 Week High | $42.86 | $87.83 |
| Indicator | CUBE | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 54.10 | 66.01 |
| Support Level | $38.98 | $70.05 |
| Resistance Level | $42.44 | N/A |
| Average True Range (ATR) | 0.78 | 4.07 |
| MACD | -0.05 | 0.64 |
| Stochastic Oscillator | 70.15 | 85.35 |
CubeSmart is a real estate investment trust that acquires, owns, and manages self-storage facilities throughout the United States. The company's real estate portfolio is composed of buildings with numerous enclosed storage areas for both residential and commercial customers to rent mainly on a month-by-month basis. Majority of CubeSmart's facilities are located in Florida, Texas, California, New York, and Illinois. Cumulatively, these states account for both the majority of the square footage in the company's real estate portfolio and the majority of its revenue. The company derives nearly all of its revenue from rental income from tenants utilizing its storage facilities.
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.